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Summary
The shared exon 2 of the p14ARF-p16INK4a locus is frequently mutated in human cancers. 
However, in contrast to the exon 1β-encoded N-terminal half of ARF, the function of the exon 2-
encoded C-terminal half of ARF has been elusive. Here, we report that the mitochondrial protein 
p32/C1QBP binds the ARF C terminus. We show that p32 is required for ARF to localize to 
mitochondria and induce apoptosis, and that ARF mutations specifically disrupting p32 binding 
can impair both of these functions. Wild-type ARF, but not a p32-binding-deficient ARF mutant, 
localizes to mitochondria, reduces mitochondrial membrane potential, and sensitizes cells to p53-
induced apoptosis. These findings provide a potential explanation for the frequent human cancer 
mutations targeting the ARF C terminus.
Introduction
The mammalian p14ARF-p16INK4a locus (p19Arf in the mouse, ARF and p16 hereafter) is 
frequently mutated in human cancers at an overall frequency of approximately 40% (Kamb 
et al., 1994; Nobori et al., 1994; Ruas and Peters, 1998). This extraordinarily high incidence 
of mutation is believed to result from the gene's unusual organization. The locus contains 
three exons, designated 1α, 2, and 3, that encode the CDK inhibitor p16. About 20 kb 
upstream from exon 1α, the locus contains an additional exon, 1β, from which a second 
transcript is initiated, encoding ARF. The ARF transcript skips exon 1α and joins the 
common exon 2 in such a fashion that ARF and p16 exist in alternate reading frames with 
respect to the shared exon 2 (Sherr, 2001).
Via distinct mechanisms, ARF and p16 activate the p53- and pRb-mediated tumor 
suppression pathways, respectively. Inactivation of both pathways by loss-of-function 
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mutations represents a frequent, and perhaps obligatory, event in the development of most 
human cancers (Vogelstein et al., 2000). Targeted deletion in mice of the exon 2 shared by 
ARF and p16 was shown to result in accelerated tumor development (Serrano et al., 1996). 
Homozygous deletion of either ARF (exon 1β) (Kamijo et al., 1997) or p16 (exon 1α) 
(Krimpenfort et al., 2001; Sharpless etal., 2001) alone predisposes micetotumor 
development, indicating that both genes are bona fide tumor suppressors. Enforced ARF 
expression causes cell-cycle arrest at both the G1 and G2 phases in a p53-dependent fashion 
(Quelle et al., 1995) by binding directly to and interfering with the p53 negative-regulator 
MDM2 (Kamijo et al., 1998; Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998). 
In addition to MDM2, many other ARF-interacting proteins have been identified, including 
E2Fs, DNA topoisomerase I, Pex19p, spinophilin/neurabin II, a type 1 protein-phosphatase-
binding protein, B23/NPM, ARF-BP1, c-Myc, and CtBP (reviewed recently by Sherr, 2006).
Endogenous ARF expression is known to be elevated by oncogenic Myc, Ras, E2F1, E1A, 
and v-Abl—all of which activate p53-dependent cell-cycle arrest—leading to the proposal 
that ARF mediates a p53-dependent cell-cycle arrest checkpoint in response to oncogenic 
signals (Sherr, 1998). In addition, ARF plays an important role in apoptotic cell death. ARF 
regulates p53-mediated apoptosis that is induced by adenovirally expressed E1A and c-Myc 
(de Stanchina et al., 1998; Zindy et al., 1998). Furthermore, apoptosis is increased in mouse 
embryo fibroblast (MEF) cells engineered to overexpress c-Myc, E1A, or E2F1; however, 
this effect is not seen in ARF null MEF cells, and reintroducing ARF into the ARF null cells 
sensitizes them to apoptosis induced by these oncogenes, confirming a critical role in this 
process for ARF. ARF can also induce apoptosis in cells lacking p53, although with slow 
kinetics, indicating that ARF also has a p53-independent apoptotic function (Eymin et al., 
2003; Hemmati et al., 2002).
The shared exon 2 of the human p14ARF-p16INK4a locus suffers frequent point mutations 
in cancer that are predicted to affect the protein sequences of p16 and ARF either 
individually or simultaneously, and most of these point mutations are clustered at the 5′ 
portion of exon 2, which is shared by p16 and ARF. Of 661 cancer-derived alterations 
compiled for the entire exon 2 (Greenblatt, 2006; Greenblatt et al., 2003; Ruas and Peters, 
1998; Sharpless, 2005), 560 (85%), including 504 sporadic and 56 germline mutations, are 
clustered in the 5′ portion shared by ARF and p16 (see diagram in Figure 4B). Among these, 
118 (21%) are frame-shifting small deletions and insertions that truncate the C-terminal 
sequences of both ARF and p16, 260 (46%) are point mutations that simultaneously affect 
the sequence of both proteins, and 39 (7%) are point mutations that affect the protein 
sequence of ARF, but not p16. The presence of these cancer-associated mutations in the 
ARF C terminus suggests a potential tumor suppressor function for this region, yet a 
generally held view is that ARF is not functionally affected by these C-terminal mutations, 
because ectopic expression of the exon 1β-encoded N-terminal domain of ARF is sufficient 
to fulfill the known biological roles of the full-length ARF protein, such as association with 
MDM2 and activation of p53 to cause cell-cycle arrest. It has been shown that some exon 2 
mutations could affect the function of ARF's nucleolar localization signal, which is located 
at the C-terminal half of human ARF (Zhang and Xiong, 1999). Nevertheless, the perception 
remains that only p16, but not ARF, is functionally affected by the exon 2 mutations. Why, 
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then, the 5′ portion of exon 2 shared by p16 and ARF is preferentially subjected to cancer-
associated mutations, particularly those that are ARF specific, remains unexplained.
In this study, we have identified a binding partner for the C terminus of ARF: the 
mitochondria-anchored protein p32 (a.k.a. C1QBP, gC1qR, HABP1). Importantly, the ARF-
p32 interaction is disrupted by human cancer-derived point mutations in exon 2 of ARF, 
including mutations that affect only ARF but not p16. We show that p32 is a critical 
mediator for both ARF mitochondrial localization and ARF-induced, p53-dependent 
apoptosis. These findings provide a previously unknown apoptotic function of ARF in the 
mitochondria and a potential explanation for ARF-specific exon 2 mutations in human 
cancer.
Results
ARF Interacts with Mitochondrial Protein p32
To better understand the biological functions of ARF, we sought to identify ARF-associated 
peptides by carrying out a large-scale coimmunoprecipitation (co-IP) following adenovirus-
mediated overexpression of human ARF in cells, utilizing an antibody specific for the 
human ARF protein. A number of polypeptides were copurified with ARF protein from the 
Ad-ARF infected cells, but not from Ad-GFP infected control cells (Figure 1A). One of the 
peptides identified by mass spectrometric analysis was the mitochondrial protein p32. p32 
(a.k.a. C1QBP for globular head component factor C1q binding protein, gC1qR for receptor 
for C1q, and HABP1 for hyaluronan-binding protein 1) was originally copurified with the 
pre-mRNA splicing factor SF2/ASF in HeLa cells (Krainer et al., 1991) and was 
subsequently shown to be expressed as a pro-protein of 282 residues whose first 73 residues 
contain a mitochondrial targeting signal and are cleaved during maturation (Ghebrehiwet et 
al., 1994). p32 has been shown to be a receptor for globular head component factor C1q 
(Ghebrehiwet et al., 1994) and to play a role in RNA splicing (Petersen-Mahrt et al., 1999) 
and oxidative phosphorylation (Muta et al., 1997). It is localized predominantly in the 
mitochondrial matrix (Dedio et al., 1998; Muta et al., 1997) and was recently implicated in 
mediating cellular apoptotic response (Kamal and Datta, 2006; Sunayama et al., 2004). We 
confirmed a direct physical interaction between ARF and p32 by a coupled in vitro 
transcription/translation (IVT) assay using 35S-labeled p32 and ARF proteins (Figure 1B). A 
direct and specific interaction between ARF and p32 was further confirmed by a GST 
pulldown assay (data not shown). The in vivo ARF-p32 interaction was demonstrated by co-
IP of endogenous ARF with ectopically expressed Myc-p32 in H1299 cells (p53 negative, 
ARF positive) (Figure 1C), and reciprocally of endogenous p32 with ectopically expressed 
ARF in U2OS cells (ARF negative) (Figure 1D). Furthermore, we were able to show the 
ARF-p32 association in Raji cells, which express endogenous ARF and p32, under 
unstressed physiological conditions (Figure 1E). Finally, we found that the physiological 
ARF-p32 interaction was enhanced by treating cells with a low dose(5 nM) of actinomycin 
D, which is known to delocalize ARF from the nucleolus to the nucleoplasm (Lindstrom et 
al., 2000), suggesting that the interaction takes place preferentially outside of the nucleolus 
(Figure 1F). Together, these data indicate that p32 interacts with ARF both in vitro and in 
vivo under physiological conditions.
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p32 Is Critical for a Subset of ARF to Localize to Mitochondria
The findings that p32 is predominantly a mitochondrial protein while ARF is usually in the 
nucleolus raise a question about the sub-cellular compartment in which the two proteins 
might interact or colocalize. To address this question, we fractionated cell lysates into 
cytoplasmic (Cyto) and mitochondrial (Mito) fractions and examined the existence and the 
relative abundance of ARF and p32 in each of the fractions. We chose two human cancer 
cell lines (H1299 and HCC1937)and a MEF cell strain(p53 null) for the study, based on the 
feature that they all express a relatively high level of ARF protein due to their p53-negative 
status. We tested several fractionation protocols and found that a combination of a hypo-
tonic buffer, digitonin, and Triton X-100 (see Experimental Procedures) yields the cleanest 
cytoplasmic and mitochondrial fractions, which do not contain detectable contaminations 
from each other or from nuclear proteins (Figure 2A). With this fractionation scheme, we 
detected a subset of total ARF protein in the mitochondrial fractions from each of the cells 
(Figure 2A). On the other hand, p32 was found exclusively in the mitochondria, as 
previously reported (Dedio et al., 1998; Muta et al., 1997). These evidences show that ARF 
and p32 colocalize in the mitochondria and suggest that the ARF-p32 interaction might be 
important for ARF's mitochondrial localization.
To study the role of p32 in ARF's localization to the mitochondria, we knocked down p32 in 
H1299 and HCC1937 cells by siRNA, fractionated the cell lysates, and examined the level 
of mitochondrial ARF by western blotting. In both H1299 and HCC1937 cells, transfection 
of the p32 siRNA led to approximately 70%–80% reduction of endogenous p32. This 
amount of p32 reduction did not affect the total level of ARF expression, nor did it 
apparently affect the growth properties of the cells (data not shown). Importantly however, 
we observed a significant reduction of the level of ARF in the mitochondria, and the 
reduction was roughly in proportion with the level by which p32 was reduced (Figure 2B). 
Similar results were also seen in U2OS cells (p53 positive, ARF negative) with ectopically 
expressed ARF (Figure S1A available online) and in primary MEFs with onco-gene-induced 
ARF (Figure 2C). Furthermore, coexpression of ARF and p32 significantly increased the 
level of ARF protein in the mitochondrial fraction without changing the total ARF level 
(Figure S1B), indicating that a high level of p32 facilitates ARF's mitochondrial localization. 
Thus, these findings indicate that p32 is critical for a subset of ARF protein to localize to the 
mitochondria, and this can occur both in unstressed ARF-expressing tumor cells and in 
oncogene-challenged normal fibroblast cells.
p32 Is Critical for ARF-Induced Apoptosis
To elucidate the functional significance of mitochondrial ARF and its interaction with p32, 
we wanted to determine whether p32 plays any role in ARF-induced cell-cycle arrest and/or 
apoptosis. We carried out our study first in U2OS cells because the cells undergo both 
growth arrest and apoptosis upon ectopic ARF overexpression (Hemmati et al., 2002; Kim et 
al., 2004; Yarbrough et al., 2002). We first reduced p32 expression by transfection of p32 
siRNA before infecting the cells with adenovirus expressing ARF. We then examined cell 
death by microscopic observation. Adenovirus-mediated ARF overexpression yielded 
extensive cell death in U2OS cells; after 2 days of infection, only about 25% of cells 
remained attached to the control plate transfected with scrambled siRNA (Figure 3A, open 
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bar, and Figure S2, panel 2). In contrast, in samples transfected with p32 siRNA, more than 
70% of cells survived ARF overexpression and remained attached to the plate (Figure 3A, 
filled bar, and Figure S2, panel 4). We next examined the cells by flow cytometry analysis. 
Knocking down p32 resulted in a significant reduction in ARF-induced apoptosis (measured 
by percentage of cells in sub-G1 phase) but had virtually no effect on ARF-induced S phase 
reduction (Figure 3B), indicating that p32 is important only in mediating ARF-induced 
apoptosis, but not growth arrest. Consistent with this notion, western blotting analysis 
indicated that a reduction of p32 attenuated ARF-mediated PARP (poly ADP ribose 
polymerase) cleavage—a characteristic of cells undergoing irreversible apoptosis—but did 
not affect ARF's induction of p53 (Figure 3C).
To further analyze the apoptotic role of p32 under a more physiological condition, we tested 
whether inhibition of p32 expression could affect Myc-induced ARF-dependent apoptosis in 
primary MEFs. For this purpose, early passage (P1–P3) wild-type MEFs were engineered to 
stably express either pBabe vector (control) or pBabe-Myc. Apoptosis was subsequently 
triggered by culturing near-confluent cells in serum-free medium for 24 hr, and the cells 
surviving the treatment (those that remained attached to the plate) were counted. As shown 
in Figure 3D, in samples transfected with scrambled siRNA (si-Scr), a combination of Myc 
overexpression and withdrawing serum led to cell death in a majority of the cell population, 
with only approximately 30% of cells remaining attached to the plate (Figure 3D, column 4, 
open bar). In contrast, in samples transfected with p32 siRNA (si-p32), more than 70% of 
cells survived the treatment (Figure 3D, column 4, filled bar), indicating that Myc-induced 
cell death in the primary MEFs depends on p32. To further demonstrate that the reduction in 
cell death was due to inhibition of apoptosis, we analyzed PARP cleavage in the MEFs by 
western blotting. pBabe-mediated Myc overexpression resulted in activation of ARF in the 
cells (Figure 3E, ARF panel). A combination of Myc overexpression and withdrawing 
serum resulted in PARP cleavage (Figure 3E, lanes 7), and this was relegated by depletion 
of p32 (Figure 3E, lanes 8). To rule out a potential off-target effect of the p32 siRNA, we 
used a second pair of p32 siRNA oligomers (si-p32-2), which produced identical results 
(Figure 3E, lanes 9 and 10). Together, these results indicate that p32 is a critical mediator for 
ARF-induced apoptosis but is perhaps irrelevant to ARF-induced cell-cycle arrest.
Human Cancer-Derived ARF C-Terminal Mutations Impair p32 Binding
To better understand the nature of ARF-p32 binding, we identified the protein sequence in 
ARF that mediates its interaction with p32. We constructed a series of Myc-tagged ARF 
deletion mutants, transiently expressed them in U2OS cells, and determined the interaction 
of each mutant protein with endogenous p32 by an IP-western assay. Notably, unlike other 
ARF-interacting proteins such as MDM2 and B23 that interact with the exon 1β-encoded N 
terminus of ARF, p32 interacted with ARF via a sequence between residues 82 and 101 (aa 
numbers corresponding to human ARF) in the exon 2-encoded C-terminal half of the ARF 
protein (Figure 4A). Intriguingly, human cancer-derived small mutations are frequently 
observed in exon 2 of the ARF-INK4a gene locus, and these mutations are clustered at the 5′ 
portion of exon 2 that is shared by ARF and p16 (Figure 4B). Previous studies have shown 
that p32 interacts with several viral and cellular proteins at sequence domains rich in 
arginine (Arg) (Figure S3) (Beatch et al., 2005; Hall et al., 2002; Luo et al., 1994; 
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Nikolakaki et al., 1996; Wang et al., 1997). The ARF protein is rich in Arg (24 Arg among 
132 residues in human ARF; 18%), especially within the area mapped for p32 binding, 
where 8 out of the 20 residues (40%) are Arg (Figure 4C). Cancer mutations affecting each 
of the eight Arg residues within the p32 binding area have been reported, and many of these 
mutations are ARF specific (i.e., not affecting p16 due to alternative reading frames). To 
determine whether any of these Arg mutations might affect the ARF-p32 interaction, we 
constructed ARF mutants according to reported Arg mutations and tested them for p32 
binding in transiently transfected cells. Remarkably, each of the Arg mutations within the 
p32-binding domain significantly affected the ARF-p32 interaction (Figure 4D, lanes 3–10), 
whereas non-Arg mutations (P94L, P94S, L104I) and an Arg mutation (R115G) outside of 
the p32-binding domain did not(Figure 4D,lanes 11–14). None of the Arg mutations 
disrupted the interaction of ARF with MDM2 or B23, suggesting that the impairment of 
ARF-p32 binding by the Arg mutations is p32 specific (Figure 4D, MDM2 and B23 panels). 
Hence, these data show that the ARF-p32 interaction specifically can be impaired by cancer-
derived mutations targeting the ARF C terminus.
p32-Binding-Deficient ARF Mutants Are Attenuated in Apoptotic Function
To study how the mutations disrupting p32 binding could affect ARF function, we 
constructed two adenoviruses expressing ARF mutants (RR98,99LS and R98Q, designated 
RR and R), according to hotspot mutations found in human patients (Figure 4B, shown with 
asterisks), and compared growth arrest and apoptosis in U2OS cells expressing the mutant 
ARF. Consistent with findings from our earlier experiments (Figure 3) and others (Hemmati 
et al., 2002; Kim et al., 2004; Yarbrough et al., 2002), over-expression of wild-type ARF 
caused both cell-cycle arrest and apoptosis in U2OS cells: the cell population in S phase 
(Figure 5A, open bar) was reduced from approximately 28% to 11%, while the population in 
sub-G1 increased from 1% to about 24% (Figure 5A, filled bar). Notably, however, although 
overexpression of each ARF mutant (RR and R) resulted in an equivalent level of cell-cycle 
arrest as that caused by wild-type ARF expression, the mutant ARF caused only a moderate 
increase in apoptosis (Figure 5A, filled bar), despite expression of the mutant proteins at 
equivalent or higher levels compared to wild-type ARF (see inset in Figure 5A). These data 
indicate that the ARF C-terminal mutants are impaired selectively in their apoptotic 
function. To further investigate ARF's apoptotic function, we examined PARP cleavage in 
cells overexpressing the ARF mutants. As determined by immunostaining of ARF, 
increasing amounts of moi (multiplicity of infection) result in higher levels of ARF 
expression in each of the infected cells (data not shown). As shown in Figure 5B, even 
though PARP cleavage could be seen in cells infected with adenoviruses expressing each of 
the ARF proteins, including the mutants, the extent of PARP cleavage was evidently lesser 
in cells expressing the ARF mutants than in cells expressing wild-type ARF (Figure 5B). In 
contrast, the induction of p53 by ARF was unaffected by these Arg mutations (Figure 5B, 
p53 panel). These results, together with the cell-cycle studies shown in Figure 5A, suggest 
that ARF's apoptotic function is selectively affected by cancer-associated C-terminal Arg 
mutations that disrupt its binding with p32.
To investigate whether p32 could augment ARF's apoptotic activity, we ectopically 
expressed p32 in U2OS cells along with ARF or the ARF mutants and examined PARP 
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cleavage by western blotting. ARF overexpression was adjusted to a low level so that it 
would not by itself cause apoptosis in the cells. Coexpression of p32 with wild-type ARF 
increased PARP cleavage (Figure 5C, lane 5); in contrast, the p32-binding-deficient ARF 
mutant was unresponsive to p32 overexpression, and PARP cleavage was not observed 
(Figure 5C, lane 6). Of note, overexpression of p32 did not stabilize endogenous p53, nor 
did it by itself induce PARP cleavage (Figure 5C, lane 4). The ability of p32 to augment 
ARF's apoptotic function was further examined by flow cytometry analysis. Consistently, 
p32 enhanced ARF-induced apoptosis specifically, but not cell-cycle arrest, and this 
synergistic effect was not observed when p32 was coexpressed with the p32-binding-
deficient ARF mutant (Figure 5D). Together, these data indicate that p32 augments ARF-
induced apoptosis specifically, and this function of p32 requires ARF-p32 physical 
association.
Wild-Type ARF, but Not a p32-Binding-Deficient ARF Mutant, Reduces Mitochondrial 
Membrane Potential and Synergizes with p53 to Induce Apoptosis
To explore possible mechanisms by which the p32-binding-deficient ARF mutant is 
impaired in its apoptotic function, we examined whether the ARF-p32 physical interaction is 
required in order for ARF to localize to the mitochondria. We expressed both the wild-type 
ARF and the p32-binding-deficient ARF (RR) mutant in cells and examined the level of 
each ARF protein present in the mitochondrial fraction by western blotting. Using the same 
fractionation scheme and H1299 cells as shown in Figure 2, we were able to obtain 
mitochondrial fractions containing no detectable nuclear or cytoplasmic proteins. We found 
that ectopically expressed wild-type ARF could be readily detected in the mitochondria, 
while the RR mutant, although expressed at the same level, was much less efficient in 
localizing to the mitochondria (Figure 6A). A similar observation was also made in U2OS 
cells (data not shown). This finding is consistent with the idea that the ARF-p32 interaction 
is required to mobilize ARF to the mitochondria.
It has been shown that a decrease in the mitochondrial inner membrane potential (Δψm) is 
associated with early onset of apoptosis (Green and Kroemer, 2004). To study the functional 
significance of ARF's mitochondrial localization, we examined Δψm in cells in the presence 
of both wild-type and RR mutant ARF. We chose p53-negative H1299 and MDA468 cells 
for the experiment in order to avoid ARF-induced, p53-dependent rapid apoptosis and, more 
importantly, to allow us to examine ARF's function in mitochondria without the interference 
of p53 activity. The Δψm was analyzed by incubating the cells with JC-1 dye (Cell 
Technology, Inc., Mountain View, CA) followed by flow cytometry analysis. We adjusted 
ARF expression to a moderate level by reducing the moi so that it would not cause apoptosis 
in the cells. Under such conditions, we observed an evident decrease in Δψm in cells 
expressing wild-type ARF, but much less so in cells expressing the RR mutant ARF (Figure 
6B). The same results were also obtained in p53-negative Saos2 and HeLa cells (data not 
shown). The decrease in Δψm as a consequence of ARF expression was also observed in 
U2OS (p53-positive) cells (Figure S4), suggesting that ARF's ability to decrease Δψm is a 
general phenomenon and possibly p53 independent. To assess the physiological role of ARF 
in mitochondria, we examined Δψm in primary MEFs under mitochondrial stress induced by 
oligomycin–an inhibitor of mitochondrial ATP synthase (Chappell and Greville, 1961) that 
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is widely used to impose mitochondrial stress in cultured cells. We treated p53 null (p53−/−) 
and ARF/p53 double null (p19Arf−/−;p53−/−) MEFs with 2 μg/ml of oligomycin and 
examined their Δψm. In the presence of oligomycin treatment, a reduction of Δψm was 
observed in both MEFs, without signs of apoptosis. However, the reduction was much more 
pronounced in p53−/− MEFs than in p19Arf−/−;p53−/− MEFs (Figure 6C). Together, these 
observations suggest that the presence of ARF in the mitochondria sensitizes cells to 
mitochondrial stress and leads to loss of Δψm, but not necessarily apoptosis, which might 
also require the presence of p53.
Previous studies have shown that ARF-induced apoptosis is mostly dependent on the 
function of p53. In the absence of p53, ARF induces apoptosis only at a nonphysiological 
high level of expression, and with slow kinetics. Consistent with this notion, we have 
observed that, in both ARF-overexpressing H1299 cells and oligomycin-treated p53−/− 
MEFs, even though the loss of Δψm was evident, apoptosis did not occur. Because release of 
cytochrome c from the mitochondrial intermembrane space into the cytoplasm is considered 
a key initiative step in the apoptotic process (Jiang and Wang, 2004), we therefore examined 
whether or not this ARF-induced loss of Δψm leads to cytochrome c release (Figure 7A). We 
infected p53-negative H1299 and p53-positive U2OS cells with increasing amounts of ARF 
adenovirus. Two days after infection, cell lysates were collected, soluble cytoplasmic 
(mitochondria-free) fractions were purified, and the presence of cytochrome c in the 
cytoplasmic fractions was analyzed by western blotting. Interestingly, even though ARF was 
expressed to even higher levels (by increasing moi) than those achieved in the Δψm assay, 
cytochrome c release was not observed in ARF virus-infected H1299 (p53-negative) cells. In 
contrast, the same level of ARF overexpression in U2OS (p53-positive) cells triggered 
cytochrome c release, consistent with the observed apoptosis in ARF-overexpressing U2OS 
cells (Figures 3A–3C). These findings, together with the results from the Δψm assay, suggest 
that ARF, although ineffective in causing apoptosis by itself, sensitizes cells to p53-induced 
apoptosis.
To test this hypothesis directly, we ectopically expressed ARF and p53 either individually or 
together in p53-negative Saos2 cells and examined PARP cleavage. We adjusted p53 
expression to a low level so that it alone would cause only marginal PARP cleavage in 
Saos2 cells, and we adjusted ARF expression to a level equivalent to that of endogenous 
ARF in H1299 cells (see Figure 7B, ARF panel in lanes 4–5). When expressed together, 
however, the same low levels of ARF and p53 led to extensive PARP cleavage (Figure 7B), 
indicating that ARF sensitizes cells to p53-induced apoptosis. To study the role of ARF in 
p53-induced apoptosis in a more physiological setting, we transiently expressed increasing 
amounts of p53 in p53−/− and p19Arf−/−;p53−/− MEFs and examined cytochrome c release 
by western blotting. As shown in Figure 7C, in the p19Arf−/−; p53−/− MEFs, a small amount 
of cytochrome c release was observed only with a high level of p53 expression (lane 4). 
However, in the p53−/− MEFs, which contain endogenous ARF, cytochrome c release was 
observed with the lowest level of p53 expression; this effect was even more pronounced 
with a higher level of p53 (lanes 6–8). These results indicate that an endogenous level of 
ARF is able to sensitize cells to p53-induced apoptosis.
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In the present study, we report identification of the mitochondrial protein p32 as an ARF C-
terminal domain-associated protein whose association with ARF can be disrupted by human 
cancer-derived point mutations in exon 2 of the p14ARF-p16INK4a gene locus. We found 
that both p32 and ARF-p32 binding are required for a subset of ARF protein to mobilize to 
the mitochondria (Figures 2 and 6). siRNA-mediated downregulation of p32 by up to 80% 
did not affect cell growth and proliferation noticeably but significantly inhibited apoptosis 
caused by either ectopic overexpression of ARF in p53-positive tumor cells or induction of 
endogenous ARF in wild-type MEFs (Figure 3), indicating that p32 is an essential mediator 
of oncogenic insult-induced, ARF-mediated apoptosis. The identification of p32 as an 
essential mitochondrial binding partner for ARF and a key modulator of ARF-induced, p53-
dependent apoptosis extends the complex relationship between ARF and p53.
We adapted a mitochondrial fractionation protocol from Ramsby and Makowski (1999) and 
were able to isolate clean mitochondrial fractions (Figure 2A). With this method, we have 
investigated the physiological function of ARF in the mitochondria. We unexpectedly found 
that, at least in various p53-negative cancer cells and p53−/− MEFs, a subset of full-length 
ARF protein is in the mitochondria. Our study indicates that the localization of ARF in the 
mitochondria reduces Δψm. This function of ARF is likely independent of p53, because it 
was similarly observed in both p53-positive and p53-negative cells. However, ARF-
mediated reduction of Δψm did not lead to apoptosis in p53-negative cells, but did so only in 
the presence of p53 (Figure 7), indicating that a functional collaboration between ARF and 
p53 is required for ARF-induced apoptosis to occur. Our data are consistent with a model in 
which physiological ARF and p53 must collaborate to induce efficient mitochondria-
mediated apoptosis (Figure 8). In this model, ARF, following induction by oncogenic 
insults, inhibits the E3 function of MDM2 via the exon 1β-encoded N terminus, thereby 
stabilizing and activating p53 in the nucleus. Meanwhile, a subset of ARF interacts with p32 
via the exon 2-encoded C terminus and mobilizes to the mitochondria, where it causes a 
decrease in Δψm. The activation of p53 leads to further permeabilization of the ARF-
weakened mitochondrial membrane, resulting in release of mitochondrial contents—such as 
cytochrome c—and apoptotic cell death. Without p32 and/or mitochondria-localized ARF, 
p53-induced cell-cycle arrest may still take place normally, but apoptosis will be attenuated. 
This model is consistent with the findings that downregulation of p32 by siRNA blocks 
ARF-induced apoptosis specifically, but not cell-cycle arrest (Figure 3), and that the p32-
binding-deficient ARF mutants are impaired only in their apoptotic, but not cell-cycle arrest, 
functions (Figure 5); in both cases, ARF's induction of p53 is unaffected. It has been 
reported recently that a short isoform of ARF (smARF) translated from an internal 
methionine localizes to the mitochondria through its interaction with p32 (Reef et al., 2007), 
and when overexpressed, smARF causes autophagic cell death (Reef et al., 2006). However, 
we were unable to detect smARF in the mitochondrial fractions using our fractionation 
protocol, although we did find a small amount (∼1%–5% of total ARF) of smARF in the 
total cell lysate in various human tumor cell lines (data not shown). The reason for this 
discrepancy remains to be determined.
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Studies of cultured cell lines have shown that cancer-associated mutations in ARF and p53 
are general mutually exclusive (Stott et al., 1998). One plausible explanation for this 
observation, according to the results presented in current study, could be that ARF and p53 
may depend on each other to induce apoptosis. For example, a moderate level of p53 
activation in the absence of ARF (or mitochondrial ARF in particular) may be sufficient to 
cause growth arrest, but not apoptosis. The same level of p53, however, could be sufficient 
to cause apoptosis if ARF is present in the mitochondria and therefore able to reduce Δψm. 
Thus, the level of p53 activation in response to different environmental cues, together with 
the status of ARF, could eventually dictate the fate of the cells committing to either growth 
arrest or apoptosis.
It is interesting to speculate that p32 might be mutated in the course of cancer development, 
given its role in mediating ARF- and p53-induced apoptosis. However, we have not found 
reports indicating whether p32 is mutated in human cancer. Instead, it has been shown that 
p32 is overexpressed in certain cancer cells (Rubinstein et al., 2004). This finding is not 
surprising because, in addition to its apoptotic role, as we found in this study, p32 also plays 
important housekeeping roles in RNA splicing (Petersen-Mahrt et al., 1999) and oxidative 
phosphorylation (Muta et al., 1997). Cancer cells, which are more metabolically active, may 
require more p32 to sustain fast growth and proliferation. Furthermore, p32 is a downstream 
mediator of apoptosis for tumor suppressor ARF, which itself is frequently mutated in 
cancer. Mutations in the upstream tumor suppressor ARF could release the pressure for 
mutations in the downstream p32.
Based mostly on in vitro overexpression systems, several published studies imply that the 
ARF N-terminal region encoded by exon 1β is sufficient for all known functions of the ARF 
protein, leading to the notion that the exon 2-encoded ARF C terminus does not possess any 
function (Kim et al., 2003; Lohrum et al., 2000; Midgley et al., 2000; Quelle et al., 1997; 
Stott et al., 1998; Weber et al., 2000; Zhang et al., 1998). Intriguingly, however, data from 
human cancer studies find that the majority of small mutations in the p14ARF-p16INK4a 
gene locus cluster in the 5′ portion of exon 2 that is shared by p16 and ARF, including those 
that are ARF specific, suggesting a tumor-suppressive role for the ARF C terminus. Our 
findings that ARF-induced apoptosis requires association of p32 with the exon 2-encoded C 
terminus, and that both the ARF-p32 association and ARF's apoptotic function can be 
simultaneously disrupted by single point mutations found in human cancers, has assigned a 
potential tumor-suppressive function to the ARF C terminus. Whether or not our in vitro 
data recapitulate the functional interaction of ARF and p32 under a truly physiological 
environment can only be determined definitively by introducing mutations into laboratory 
animals. Nonetheless, this study has demonstrated a promising role for p32 as a critical 
mediator of apoptosis, and these findings provide a basis for further investigation into the 
role of p32 in cancer development.
Experimental Procedures
Cell Lines, Cell Culture, and Reagents
U2OS, H1299, HCC1937, MDA-MB-468, and Saos2 cells were obtained from ATCC. Raji 
and HL60 cells were gifts from Dr. Beverly S. Mitchell (Stanford). p19Arf−/−;p53−/− MEFs 
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were a gift from Dr. Norman Sharpless (UNC-Chapel Hill). All cells were cultured in a 
37°C incubator with 5% CO2 in DMEM supplied with 10% FBS. After each treatment, cell 
viability was determined microscopically by trypan blue exclusion, and cell number was 
counted with a hematocytometer.
Plasmids, Adenoviruses, and Flow Cytometry Analysis
Full-length p32 cDNA was purchased from Open Biosystems (GenBank accession number 
BC000435), and both untagged and Myc-tagged full-length p32 (aa 1–282) were cloned into 
a pcDNA3.1 vector (Invitrogen). All cloned constructs were confirmed by direct DNA 
sequencing. Recombinant adenoviruses carrying untagged p32, ARF, ARF mutants, p53, 
and GFP were produced using the AdEasy XL Adenoviral Vector System (Stratagene) 
according to the manufacturer's protocol. The multiplicity of infection (moi) to achieve more 
than 90% of cells infected by the adenovirus was determined by immunofluorescence 
staining before carrying out experiments. Retroviruses expressing c-Myc proteins were 
produced as described previously (Itahana et al., 2003). ARF point mutations were 
introduced by PCR-based site-directed mutagenesis. For flow cytometry analysis, both 
floating and attached cells were collected, fixed with 70% ethanol, stained with propidium 
iodide, and analyzed at the UNC Lineberger Cancer Center Flow Cytometry Facility. The 
software packages Summit (DakoCytomation) and ModFit LT (Verity) were used for flow 
cytometry data acquisition, and all flow cytometry data are representative of at least three 
independent experiments.
Protein Analysis
Rabbit polyclonal anti-p32 antibody was produced using a synthetic peptide 
(CEERKIQKHKTLPKMSG) corresponding to amino acid residues 92–107 of human p32. 
Antibodies for cytochrome c (7H8.2C12, BD PharMingen), mtHSP70/GRP75 (H155, Santa 
Cruz), p19Arf (5-C3-1, Santa Cruz), Histone H3 (9715, Cell signaling), PARP(C2-10, BD 
PharMingen), B23(Fc-61991, Invitrogen/Zymed), Actin (MAB1501, Chemicon 
International), and MDM2 (4B11, Calbiochem) were purchased commercially. Antibodies 
for human ARF (P02; N terminus epitope), p53 (DO1), Tubulin (DM1A+DM1B), and Myc 
(9E10.3) were purchased from Lab Vision/Neomarker. Rabbit polyclonal antibodies to Myc, 
human ARF (C terminus epitope), and mouse ARF (C terminus epitope) were gifts from Dr. 
Yue Xiong (UNC-Chapel Hill). The in vitro transcription/translation (IVT) assay is 
described elsewhere (Enomoto et al., 2006). Cells were lysed in 0.1% NP-40 buffer for 
immunoprecipitation and 0.5% NP-40 buffer for straight western blotting unless otherwise 
stated. For analysis of PARP cleavage, both floating and attached cells were collected.
RNA Interference
The siRNA oligonucleotides targeting p32 mRNA, and the control scrambled 
oligonucleotides (si-Scr), were synthesized either commercially by Dharmacon (Lafayette, 
CO) or by using the Silencer siRNA Construction Kit (Ambion, TX). The two targeting 
sequences for p32 are 5′-GGUUGAAGAACAGGAGCCUdTdT-3′ (si-p32) and 5′-
UCACGGUCACUUUCAACATdTdT3′ (si-p32-2) (Sunayama et al., 2004). siRNA 
oligonucleotides (80 pmol) were transfected using Oligofectamine (Invitrogen) or 
Itahana and Zhang Page 11













Lipofectamine (Invitrogen) in a 35 mm dish according to the manufacturer's protocol. All 
cultures were performed without antibiotics during siRNA transfection. For adenovirus 
infection after transfection, cells were transfected with siRNA oligonucleotides for 1–2 days, 
washed with medium, and infected with adenovirus for another 1–2 days.
Cytoplasmic and Mitochondrial Fractionation
Cytoplasmic extracts were prepared using a low concentration (0.15 mg/ml) of digitonin 
solution adapted from Hemmati et al. (2006). Mitochondrial extracts were prepared using a 
low concentration (0.5%) of Triton X-100 (Fisher Scientific) solution adapted from Ramsby 
and Makowski (1999) with slight modifications. Briefly, both attached and floating cells 
were collected by centrifugation and washed twice with PBS. One-fourth of the cells were 
lysed with SDS lysis buffer (100 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol) for direct 
SDS-PAGE analysis. The remaining cells were lysed in cold hypotonic buffer (20 mM 
HEPES [pH 7.4], 10 mM KCl, 2 mM MgCl2, 1 mM EDTA) supplemented with freshly 
made 1 mM PMSF and 0.15 mg/ml digitonin (Sigma). After incubation on ice for 3 min, 
cellular debris, including nuclei and mitochondria, were pelleted in a microcentrifuge 
(12,000 rpm) for 10 min at 4°C. The supernatants were transferred to a fresh tube as the 
cytoplasmic fraction. The cell pellets were further washed twice with cold hypotonic buffer 
with 1 mM PMSF and then pelleted by centrifugation (12,000 rpm, 2 min). The digitonin-
insoluble pellets (containing mitochondria) were lysed with cold 0.5% Triton X-100/
hypotonic buffer with 1 mM PMSF and incubated on ice for 1 min. Subsequently, cellular 
debris including intact nuclei were pelleted in a microcentrifuge (12,000 rpm) for 5 min at 
4°C, and the supernatants were transferred to a fresh tube as the mitochondrial fraction. Both 
cytoplasmic and mitochondrial fractions were mixed with 5× SDS-PAGE loading buffer 
before loading onto the gel.
Measurement of Mitochondrial Membrane Potential
Both attached and floating cells were collected and washed twice with culturing medium. 
Equal concentrations of cells (1 × 106 cells/ml) were incubated for 15 min in culture 
medium containing 1× JC-1 dye (Cell Technology, Inc., Mountain View, CA) at 37°C in a 
5% CO2 incubator according to the manufacturer's instructions. Cells were washed three 
times with culturing medium and analyzed by flow cytometry in the FL-1 and FL-2 
channels. Mitochondrial permeability transition was assessed with decreased red 
fluorescence (FL-2), which indicates the presence of mitochondria with a lower membrane 
potential (Δψm).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Although ARF's cell-cycle arrest function is well understood, little is known about ARF's 
role in apoptosis, due largely to the lack of specific molecules linking ARF to this 
process. The current view holds that the C terminus of ARF is dispensable for tumor 
suppression because overexpression of the ARF N-terminal half alone is sufficient to 
activate p53. The study reported here identifies mitochondrial p32 as a binding partner of 
ARF's C terminus and a critical mediator of ARF's apoptotic function in the 
mitochondria. Importantly, the ARF-p32 interaction and ARF's apoptotic function are 
simultaneously disrupted by cancer-derived point mutations in the ARF C terminus. Our 
results provide mechanistic insight into ARF-induced, p53-dependent apoptosis and 
demonstrate a potential tumor-suppressive function for the ARF C terminus.
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Figure 1. ARF Interacts with p32
(A) Identification of ARF binding proteins by mass spectrometry. Extracts from U2OS cells 
infected with adenovirus expressing GFP or ARF were immunoprecipitated with an anti-
ARF antibody, resolved by SDS-PAGE, and visualized by silver staining. Peptide bands 
unique to samples infected with Ad-ARF were subjected to mass spectrometry. ARF, p32, 
B23 (a known ARF-binding protein), and IgG heavy and light chains (IgG-H and IgG-L) are 
indicated.
(B) Direct interaction between p32 and ARF. Full-length p32 and ARF were in vitro 
translated in the presence of 35S-methionine. Equal amounts of p32 protein were incubated 
with (+) or without (−) ARF followed by immunoprecipitation with an anti-ARF antibody. 
The resulting ARF immunoprecipitates were separated by SDS-PAGE and visualized by 
autoradiography.
(C) Coimmunoprecipitation (co-IP) of endogenous ARF with ectopically expressed p32. 
H1299 cells (p53-negative, ARF-positive) were transfected with Myc-p32 plasmid for 2 
days, and cell extracts were immunoprecipitated with anti-Myc antibody. Western blotting 
was performed with anti-Myc and anti-ARF antibodies. Loading control represents 10% of 
cell lysate used for co-IP.
(D) Co-IP of endogenous p32 with ectopically expressed ARF. Extracts from U2OS cells 
infected with Ad-ARF were immunoprecipitated with anti-ARF antibody. Western blotting 
was performed with anti-ARF and anti-p32 antibodies. Loading control represents 
approximately 10% of cell lysate used for co-IP.
(E) Co-IP of ARF with p32from Raji cells. Cell extracts from Raji (Burkitt's lymphoma, 
expressing endogenous ARF and p32) cells were immunoprecipitated with anti-ARF 
antibody and blotted with anti-p32 and anti-ARF antibodies. HL60 (leukemia, ARF-
negative) cells served as a negative control.
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(F) Increased ARF-p32 interaction following actinomycin D treatment. H1299 cells were 
treated with (+) or without (−) 5 nM actinomycin D for 36 hr. Cell extracts were 
immunoprecipitated with anti-ARF antibody and blotted with anti-p32 and anti-ARF 
antibodies. Extracts from U2OS (ARF-negative) cells served as a negative control. Loading 
control represents approximately 10% of cell lysate used for co-IP.
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Figure 2. p32 Is Critical for a Subset of ARF to Localize to Mitochondria
(A) Mitochondrial localization of endogenous ARF. p53-negative H1299 and HCC1937 
cells, and p53−/− MEFs were either prepared as SDS lysates (Total) or separated into 
cytoplasmic (Cyto) and mitochondrial (Mito) fractions. Equal amounts of protein were 
loaded in each lane. The membrane was blotted with antibodies to p14ARF, p19Arf, p32, 
mt-Hsp70 (mitochondrial heat shock protein 70, a mitochondrial protein marker), Histone 
H3 (a nuclear protein marker), and Actin (a cytoplasmic protein marker).
(B) Downregulation of p32 by siRNA inhibits ARF mitochondrial localization. H1299 and 
HCC1937 cells were transiently transfected with a scrambled siRNA (si-Scr) or a p32 
siRNA (si-p32) for 3 days. The cells were then isolated for mitochondrial fractions and 
analyzed by western blotting with indicated antibodies.
(C) Downregulation of p32 by siRNA inhibits localization of oncogenic Myc-induced 
mouse p19Arf to mitochondria. Freshly prepared wild-type MEFs were infected with 
retrovirus carrying either no insert (pBabe) or oncogenic c-Myc (pBabe-Myc) and selected 
with puromycin for 3 days. The cells were then transiently transfected with scrambled 
siRNA (si-Scr) or p32 siRNA (si-p32) for 3 days. Total cell lysates and mitochondrial 
fractions were prepared and analyzed by western blotting with indicated antibodies.
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Figure 3. p32 Is Critical for ARF-Induced Apoptosis
(A) p32 depletion causes resistance of cells to ARF-induced apoptosis. U2OS cells were 
transfected for 24 hr with indicated siRNA and then infected for 2 days with adenovirus 
expressing either GFP or ARF. Cells that survived ARF overexpression were counted, and 
the percentages of surviving cells relative to GFP-expressing control cells were plotted. 
Error bars represent the mean ± SD of four independent experiments.
(B) p32 depletion attenuates ARF-induced apoptosis. U2OS cells were treated as described 
in (A) and collected for flow cytometry analysis of cell-cycle profiles. The percentages of 
cells in S and sub-G1 phases are shown.
(C) p32 depletion causes resistance of cells to ARF-induced PARP cleavage. U2OS cells 
were transfected with siRNA and infected with adenoviruses as described above. Cell 
extracts were analyzed by western blotting with antibodies to indicated proteins.
(D) p32 depletion causes resistance of wild-type MEFs to c-Myc-induced apoptosis. Freshly 
prepared MEFs were infected with retrovirus carrying either no insert (pBabe) or oncogenic 
c-Myc (pBabe-Myc) and were selected with puromycin for 3 days. The cells were then 
transfected with siRNA for 2 days and subsequently cultured with (+) or without (−) serum 
for 24 hr. The percentages of cells surviving the treatment were quantified, and the results 
were plotted. Error bars represent the mean ± SD of four independent experiments.
(E) A portion of the MEFs described in (D) was analyzed for p32 knockdown, p19Arf 
expression, and PARP cleavage by western blotting. Note that a second p32 siRNA oligos 
(si-p32-2) gives rise to identical results as the first p32 siRNA (si-p32).
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Figure 4. Cancer-Derived ARF C-Terminal Mutations Impair ARF-p32 Binding
(A) Mapping of the p32 binding domain on human ARF. Extracts from U2OS cells 
transfected with plasmids encoding various ARF deletion mutants were immunoprecipitated 
with anti-Myc antibody and blotted with anti-Myc and anti-p32 antibodies. A diagram of 
human ARF is shown with the indicated p32-binding site (82–101).
(B) Cancer-derived mutations in the p14ARF/p16INK4a gene locus are clustered at the 5′ 
portion of exon 2. The reported single missense mutations that affect the p16 sequence alone 
(gray bar) or both p16 and ARF (black bar) are shown in regard to the amino acid sequence 
of p16 (Greenblatt, 2006). Hotspot mutations at Arg98 and Arg99 of human ARF, 
overlapping with His83 and Asp84 in p16, are indicated with asterisks.
(C) Amino acid sequence of the exon 2-encoded human ARF C terminus. Individual 
mutations analyzed in (D) are indicated with downward arrows.
(D) Cancer-derived ARF C-terminal Arg mutations impair p32 binding. U2OS cells were 
transiently transfected with indicated plasmids expressing various Myc-tagged ARF 
proteins. Cell extracts were immunoprecipitated with anti-Myc antibody and blotted with the 
indicated antibodies.
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Figure 5. p32-Binding-Deficient ARF Mutants Are Attenuated in Apoptotic Function
(A) ARF C-terminal Arg mutations impair ARF's apoptotic function. U2OS cells were 
infected with adenoviruses expressing either wild-type ARF (ARF) or p32-binding-deficient 
ARF RR98,99LS (RR) and ARF R98Q (R) mutants for 2 days. Cells (both floating and 
attached) were collected for flow cytometry analysis of cell-cycle distribution. The fraction 
of cells in sub-G1 phase (filled bar) and S phase (open bar) and the level of ARF protein 
expression (inset) are shown. Cell-cycle profiles are also shown to the right. Error bars 
represent the mean ± SD of three independent experiments. p < 0.01 for pairwise 
comparisons of cells in sub-G1 infected by wild-type ARF and each of the mutants.
(B) ARF C-terminal Arg mutations impair ARF-mediated PARP cleavage, but not p53 
induction. U2OS cells treated as described in (A) were analyzed for PARP cleavage and p53 
induction by western blotting.
(C) p32 enhances ARF-induced PARP cleavage. Cells were infected with adenoviruses 
expressing the indicated proteins for 2 days and then harvested to be analyzed for PARP 
cleavage. Note that p32-enhanced PARP cleavage was seen only with wild-type ARF, but 
not the p32-binding-deficient mutant ARF.
(D) p32 enhances ARF-induced apoptosis but not ARF-induced cell-cycle arrest. U2OS 
cells were infected with adenoviruses expressing the indicated proteins for 2 days and 
harvested to determine the percentages of cells in sub-G1 and S phase fractions by flow 
cytometry analysis.
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Figure 6. Wild-type ARF, but Not a p32-Binding-Deficient ARF Mutant, Localizes to 
Mitochondria and Reduces Mitochondrial Membrane Potential
(A) A p32-binding-deficient ARF mutant is impaired in mitochondrial localization. p53-
negative H1299 cells were infected with adenovirus expressing either wild-type ARF (ARF) 
or a p32-binding-deficient ARF mutant (RR). Total SDS lysates and mitochondrial fractions 
were prepared 2 days after infection and analyzed by western blotting with antibodies to 
p32, ARF, mt-Hsp70, HistoneH3, and Actin.
(B) Wild-type ARF, but not a p32-binding-deficient ARF (RR) mutant, reduces 
mitochondrial membrane potential (Δψm). p53-negative H1299 and MDA468 cells were 
either uninfected (Mock) or infected with adenoviruses expressing wild-type ARF (ARF) or 
a p32-binding-deficient ARF mutant (RR) for 2 days. Δψm was measured by incubating the 
cells with JC-1 dye followed by flow cytometry analysis. In nonapoptotic cells (high Δψm), 
JC-1 exists as a monomer in the cytosol (green, FL-1) and also accumulates as aggregates in 
the mitochondria, which stains red (FL-2). In apoptotic cells (low Δψm), JC-1 exists in 
monomeric form and stains the cytosol green. Cells with preserved Δψm are high in both 
FL-1 and FL-2 (top right of graph). Cells with loss of Δψm are high in FL-1 and low in FL-2 
(bottom of graph). Flow cytometry data plots are shown with percentage of total events 
indicated. Data are representative of three independent experiments.
(C) Endogenous ARF sensitizes cells to mitochondrial stress, leading to reduction of Δψm. 
Freshly prepared p19Arf−/−;p53−/− and p53−/− MEFs were incubated with acetone (as a 
control) or 2 μg/ml of oligomycin, an inhibitor of mitochondrial ATP synthase widely used 
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to generate mitochondrial stress in cultured cells. After 48 hr of oligomycin treatment, the 
cells were collected and analyzed for Δψm by JC-1 dye.
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Figure 7. ARF Synergizes with p53 to Induce Cytochrome c Release
(A) ARF expression did not induce cytochrome c release in H1299 cells. p53-negative 
H1299 and p53-positive U2OS cells were infected with increasing amounts of adenovirus 
expressing ARF for 2 days. Total SDS lysates and cytoplasmic fractions were prepared and 
analyzed by western blotting with indicated antibodies.
(B) ARF synergizes with p53 to induce PARP cleavage. Saos2 (p53-negative) cells were 
infected with adenovirus expressing GFP, ARF, or p53 as indicated. Cells were analyzed by 
western blotting with antibodies against the indicated proteins. Note that the level of 
ectopically expressed ARF in the Saos2 cells is comparable to that of endogenous ARF in 
the H1299 cells.
(C) A low level of p53 induces cytochrome c release in ARF-positive cells. p19Arf−/−;p53−/− 
and p53−/− MEFs were infected with adenovirus expressing p53 at a low moi. Two days 
after infection, total cell lysates and cytoplasmic fractions were prepared and analyzed by 
western blotting.
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Figure 8. A Model for the Function of Mitochondrial ARF
Nuclear ARF stabilizes and activates p53 through its N-terminal interaction with and 
inhibition of MDM2 (left). A subset of ARF also localizes to the mitochondria through its 
C-terminal interaction with mitochondrial p32 (right). The mitochondria-localized ARF 
reduces Δψm and sensitizes cells to p53-induced apoptosis.
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